Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert W Robey

Showing results (71-80 of 122) with videos related to

Pageof 13
Sort By:
Molecular Cancer Therapeutics|March 1, 2006
A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activitiesPui-Kai Li, Bulbul Pandit, Dan L Sackett, et al.
ACS Chemical Biology|June 27, 2009
Botryllamides: natural product inhibitors of ABCG2Curtis J Henrich, Robert W Robey, Kentaro Takada, et al.
Molecular Pharmacology|July 28, 2009
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug ScreenJohn F Deeken, Robert W Robey, Suneet Shukla, et al.
Molecular Oncology|June 24, 2014
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatinVictoria L Luchenko, Thomas Litman, Arup R Chakraborty, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 4, 2019
Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter FunctionAndrea N Robinson, Bethelihem G Tebase, Sonia C Francone, et al.
Molecular Pharmacology|September 25, 2024
Identification of NanoLuciferase Substrates Transported by Human ABCB1 and ABCG2 and Their Zebrafish Homologs at the Blood-Brain BarrierJohn A Quinlan, Sashank Sabbineni, Robert W Robey, et al.
Oncology Reports|January 17, 2009
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistanceZhi Shi, Smitaben Parmar, Xing-Xiang Peng, et al.
Biochemistry|April 19, 2006
Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerizationOrsolya Polgar, Csilla Ozvegy-Laczka, Robert W Robey, et al.
Frontiers in Pharmacology|June 8, 2018
Bax/Tubulin/Epithelial-Mesenchymal Pathways Determine the Efficacy of Silybin Analog HM015k in Colorectal Cancer Cell Growth and MetastasisHaneen Amawi, Noor A Hussein, Charles R Ashby, et al.
Cancer Gene Therapy|April 7, 2023
Use of CRISPR-based screens to identify mechanisms of chemotherapy resistanceGeorge Alyateem, Heidi M Wade, Aaron A Bickert, et al.
Pageof 13

Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|March 1, 2006
A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activitiesPui-Kai Li, Bulbul Pandit, Dan L Sackett, et al.
ACS Chemical Biology|June 27, 2009
Botryllamides: natural product inhibitors of ABCG2Curtis J Henrich, Robert W Robey, Kentaro Takada, et al.
Molecular Pharmacology|July 28, 2009
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug ScreenJohn F Deeken, Robert W Robey, Suneet Shukla, et al.
Molecular Oncology|June 24, 2014
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatinVictoria L Luchenko, Thomas Litman, Arup R Chakraborty, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 4, 2019
Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter FunctionAndrea N Robinson, Bethelihem G Tebase, Sonia C Francone, et al.
Molecular Pharmacology|September 25, 2024
Identification of NanoLuciferase Substrates Transported by Human ABCB1 and ABCG2 and Their Zebrafish Homologs at the Blood-Brain BarrierJohn A Quinlan, Sashank Sabbineni, Robert W Robey, et al.
Oncology Reports|January 17, 2009
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistanceZhi Shi, Smitaben Parmar, Xing-Xiang Peng, et al.
Biochemistry|April 19, 2006
Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerizationOrsolya Polgar, Csilla Ozvegy-Laczka, Robert W Robey, et al.
Frontiers in Pharmacology|June 8, 2018
Bax/Tubulin/Epithelial-Mesenchymal Pathways Determine the Efficacy of Silybin Analog HM015k in Colorectal Cancer Cell Growth and MetastasisHaneen Amawi, Noor A Hussein, Charles R Ashby, et al.
Cancer Gene Therapy|April 7, 2023
Use of CRISPR-based screens to identify mechanisms of chemotherapy resistanceGeorge Alyateem, Heidi M Wade, Aaron A Bickert, et al.
Pageof 13